ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026
More Tips From The Bandish Group
Happenings from ASCO 2026
◆
ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and…
June 9, 2026
Read More
Supply Chain Challenges in Clinical Development
◆
Mehran Bhatti, CEng, CPSM, ATMP, and Biotech Supply Chain and External Manufacturing Specialist at Accenture, takes an interesting look at…
June 4, 2026
Read More